A Phase III, Randomized, Two-armed, Double-blind, Parallel, Active-controlled Clinical Trial to Evaluate Equivalency of the Efficacy and Safety of Ocrelizumab (CinnaGen, Iran) in Comparison to Reference Product, Ocrevus (Roche, Switzerland) in Patients With Relapsing Multiple Sclerosis
Latest Information Update: 24 Oct 2022
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Sponsors CinnaGen
Most Recent Events
- 16 Oct 2022 Status changed from active, no longer recruiting to completed.
- 07 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 24 Sep 2019 New trial record